¿ Cel-Sci Corp., of Vienna, Va., said the Czech Republic¿s State Institute for Drug Control has granted permission to start a Phase II clinical trial with Cel-Sci¿s Multikine therapeutic for squamous-cell carcinoma of the head and neck. Thirty patients will be tested in the trial, expected to finish by the year¿s end. Multikine is a natural mixture of cytokines.

¿ Centocor Inc., of Malvern, Pa., and Pharmacia & Upjohn (P&U), of Bridgewater, N.J., will co-promote P&U¿s Fragmin (dalteparin sodium injection) in the U.S. Centocor will promote Fragmin to cardiovascular specialists across the U.S. after receiving marketing clearance from the FDA for a new indication for unstable angina. Fragmin, a low-molecular-weight heparin preparation, is marketed by P&U in more than 40 countries, including the U.S., for the prevention of deep-vein thrombosis in at-risk patients undergoing abdominal surgery.

¿ Genzyme General, of Cambridge, Mass., disclosed its full financial report for 1998, with earnings per share in the fourth quarter of $0.39. The company said it would create a separate division, Genzyme Surgical Products. Revenues were disclosed earlier. (See BioWorld Today, Jan. 18, 1999, p. 1.)

¿ Magainin Pharmaceuticals Inc., of Plymouth Meeting, Pa., expects to meet with FDA officials to review the outcome of the meeting of the Anti-Infectives Drug Advisory Committee. The committee, by a vote of 7 to 4, declined Thursday to recommend approval of Locilex (pexiganan acetate) cream for the treatment of infected diabetic foot ulcers. Magainin¿s stock (NASDAQ:MAGN) closed Friday at $1.718, down $2.218, or 56 percent.

¿ Techniclone Corp., of Tustin, Calif., said an abstract of its Tumor Necrosis Therapy (TNT) Phase I clinical trial results in malignant glioma (brain cancer) has been accepted by the American Society of Clinical Oncology for presentation at its 35th annual meeting in May in Atlanta. TNT-1 is in Phase II trials in the U.S. for malignant glioma, and is starting a Phase I/II clinical trial in Mexico for the treatment of pancreatic, prostate and liver cancers.

No Comments